JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Inicio・Lista de Acciones・Kura Oncology Inc

Search

Kura Oncology Inc

Cerrado

SectorSanidad

8.79 -1.01

Resumen

Variación precio

24h

Actual

Mínimo

8.73

Máximo

8.85

Métricas clave
By Trading Economics
Ingresos	-6.9M -81M
Ventas	-3.4M 17M
Margen de beneficios	-467.23
Empleados	260
EBITDA	-12M -86M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+204.11% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	50M 805M
Apertura anterior	9.8
Cierre anterior	8.79

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

176 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.575 / 6.6 Soporte y Resistencia

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 may 2026, 22:17 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 may 2026, 23:47 UTC

Ganancias

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 may 2026, 23:40 UTC

Charlas de Mercado

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 may 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Shareholders to Own About 51% of Combined Company

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Board Unanimously Endorsed, Supported Deal

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Deal Unanimously Recommended by Vault Board

4 may 2026, 22:39 UTC

Adquisiciones, fusiones, absorciones

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources to Acquire All Ordinary Shares in Vault

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources, Vault Minerals Agree to Merger of Equals

4 may 2026, 22:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 may 2026, 22:26 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 may 2026, 22:02 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 may 2026, 22:00 UTC

Charlas de Mercado

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 may 2026, 21:52 UTC

Ganancias

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 may 2026, 21:49 UTC

Ganancias

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 may 2026, 21:43 UTC

Ganancias

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 may 2026, 21:41 UTC

Ganancias

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 may 2026, 21:40 UTC

Ganancias

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

204.11% repunte

Estimación a 12 Meses

Media 28.13 USD 204.11%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

176 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Otras acciones del sector

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat